fluorouracil has been researched along with HIV Coinfection in 44 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe the case of an HIV-positive 48-year-old male patient with metastatic colorectal cancer, treated with a bevacizumab, irinotecan, fluorouracil, and leucovorin regimen, with concomitant HAART." | 7.74 | Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. ( Bearz, A; Berretta, M; Berretta, S; Fisichella, R; Lleshi, A; Nasti, G; Simonelli, C; Tirelli, U; Zanet, E, 2008) |
| "Anal cancer is an increasing issue in HIV-positive men who have sex with men (MSM)." | 6.78 | Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. ( de Vries, HJ; Dijkgraaf, MG; Prins, JM; Richel, O; van Noesel, CJ, 2013) |
| " Ocular discomfort occurred in 43 of 49 patients in the fluorouracil group versus 36 of 49 in the placebo group, epiphora occurred in 24 versus five, and eyelid skin inflammation occurred in seven versus none." | 5.22 | Topical fluorouracil after surgery for ocular surface squamous neoplasia in Kenya: a randomised, double-blind, placebo-controlled trial. ( Burton, MJ; Gichuhi, S; Kabiru, J; Macharia, E; Maina, J; Munene, R; Ollando, E; Onyuma, T; Rono, H; Sagoo, MS; Wachira, J; Weiss, HA; Zindamoyen, AM, 2016) |
| "We describe the case of an HIV-positive 48-year-old male patient with metastatic colorectal cancer, treated with a bevacizumab, irinotecan, fluorouracil, and leucovorin regimen, with concomitant HAART." | 3.74 | Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. ( Bearz, A; Berretta, M; Berretta, S; Fisichella, R; Lleshi, A; Nasti, G; Simonelli, C; Tirelli, U; Zanet, E, 2008) |
| "Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional failure (LRF) rates after definitive chemoradiation (CRT), associated with anogenital human papilloma virus, and often appears in HIV infection." | 2.84 | Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. ( Aboulafia, D; Fitzgerald, TJ; Henry, DH; Kachnic, L; Lee, JY; Mitsuyasu, R; Palefsky, J; Rajdev, L; Ratner, L; Sparano, JA; Wachsman, W, 2017) |
| "Anal cancer is an increasing issue in HIV-positive men who have sex with men (MSM)." | 2.78 | Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. ( de Vries, HJ; Dijkgraaf, MG; Prins, JM; Richel, O; van Noesel, CJ, 2013) |
| "Data on colorectal cancer in HIV-positive patients are limited." | 2.44 | FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature. ( Bearz, A; Berretta, M; Berretta, S; Del Ben, C; Di Benedetto, F; Martellotta, F; Simonelli, C; Spina, M; Tirelli, U, 2008) |
| "In response to repeated observations of cervical cancers in HIV-infected women, moderate and severe cervical dysplasia were designated as early symptomatic HIV infection (Category B) by the Centers for Disease Control and Prevention (CDC) in 1993, and invasive cervical cancer as an AIDS-defining condition (Category C)." | 2.43 | Cervical screening and management of cervical intraepithelial neoplasia in HIV-positive women. ( Bradbeer, C; Danso, D; Lyons, F, 2006) |
| "She was diagnosed with esophageal cancer (cT3N2M0, stage III)." | 1.56 | A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy. ( Asano, T; Fujiki, K; Furumoto, Y; Hayakawa, Y; Horiuchi, T; Kobayashi, K; Matsumoto, T; Matsuoka, M; Misumi, Y; Miura, N; Nozaka, T; Sakamoto, N, 2020) |
| "Treatment with uridine triacetate was arranged in the emergency department." | 1.46 | The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate. ( Geller, RJ; Morgan, BW; Santos, C, 2017) |
| "However, anal cancers are rare in patients with HIV in Japan." | 1.43 | [Squamous cell carcinoma of the anal canal treated with chemoradiotherapy in a patient with HIV]. ( Ishida, H; Mita, E; Mori, K; Nakazuru, S; Nishio, K; Sakakibara, Y; Sugimoto, A; Uehira, T; Yajima, K; Yamada, T, 2016) |
| "Anal cancer is uncommon." | 1.42 | Review of anal cancer patients at the Ottawa hospital. ( Abunassar, M; Asmis, T; Jonker, DJ; Reinders, J, 2015) |
| "The treatment of anal cancer is based on concomitant radiotherapy and chemotherapy and is associated with a nonnegligible rate of local severe toxicities that can strongly impair the quality of life." | 1.39 | Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy. ( Benezery, K; Doyen, J; Follana, P; Francois, E; Gal, J; Gérard, JP; Hannoun-Levi, JM; Ortholan, C, 2013) |
| "Sixty patients with anal cancer were identified." | 1.38 | Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. ( Alfa-Wali, M; Allen-Mersh, T; Antoniou, A; Bower, M; Gazzard, B; Nelson, M; Newsom-Davis, T; Tait, D, 2012) |
| "HIV-positive patients with squamous cell carcinoma of the canal treated at Continuum Cancer Centers-affiliated hospitals were identified from tumor registries." | 1.36 | Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer. ( Ennis, RD; Evans, A; Grossbard, M; Hauerstock, D, 2010) |
| "The median CD4 count at diagnosis of anal cancer was 209 cells/microl (range: 29-380 cells/microl), 5 had prior AIDS defining diagnoses." | 1.31 | Treatment of HIV-associated invasive anal cancer with combined chemoradiation. ( Bower, M; Cleator, S; Fife, K; Gazzard, B; Nelson, M; Phillips, R, 2000) |
| "Retrospective review of 50 MO anal cancer patients treated from 1984-1994." | 1.30 | Time-dose considerations in the treatment of anal cancer. ( Constantinou, EC; Daly, W; DeLaney, TF; Fung, CY; Kaufman, DS; Willett, CG, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (13.64) | 18.2507 |
| 2000's | 15 (34.09) | 29.6817 |
| 2010's | 19 (43.18) | 24.3611 |
| 2020's | 4 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Supapannachart, KJ | 1 |
| Kwon, CW | 1 |
| Tushe, S | 1 |
| Guest, JL | 1 |
| Chen, SC | 1 |
| Yeung, H | 1 |
| Bive, BZ | 1 |
| Sacheli, R | 1 |
| Mudogo, CN | 1 |
| Zakayi, PK | 1 |
| Bontems, S | 1 |
| Lelo, GM | 1 |
| Hayette, MP | 1 |
| Leiker, AJ | 1 |
| Wang, CJ | 1 |
| Sanford, NN | 1 |
| Aguilera, TA | 1 |
| Karri, S | 1 |
| Beg, MS | 1 |
| Kazmi, SA | 1 |
| Olson, C | 1 |
| Matthews, JA | 1 |
| Abdelnaby, A | 1 |
| Meyer, JJ | 1 |
| Folkert, MR | 1 |
| Glynne-Jones, R | 1 |
| Bhattacharjee, R | 1 |
| Kumaran, MS | 1 |
| Vinay, K | 1 |
| Hayakawa, Y | 1 |
| Kobayashi, K | 1 |
| Sakamoto, N | 1 |
| Matsuoka, M | 1 |
| Nozaka, T | 1 |
| Misumi, Y | 1 |
| Matsumoto, T | 1 |
| Miura, N | 1 |
| Furumoto, Y | 1 |
| Asano, T | 1 |
| Horiuchi, T | 1 |
| Fujiki, K | 1 |
| Richel, O | 2 |
| de Vries, HJ | 2 |
| van Noesel, CJ | 1 |
| Dijkgraaf, MG | 1 |
| Prins, JM | 2 |
| Doyen, J | 1 |
| Benezery, K | 1 |
| Follana, P | 1 |
| Ortholan, C | 1 |
| Gérard, JP | 1 |
| Hannoun-Levi, JM | 1 |
| Gal, J | 1 |
| Francois, E | 1 |
| Fraunholz, IB | 1 |
| Haberl, A | 2 |
| Klauke, S | 1 |
| Gute, P | 1 |
| Rödel, CM | 1 |
| Abunassar, M | 1 |
| Reinders, J | 1 |
| Jonker, DJ | 1 |
| Asmis, T | 1 |
| Sugimoto, A | 1 |
| Nakazuru, S | 1 |
| Sakakibara, Y | 1 |
| Nishio, K | 1 |
| Yamada, T | 1 |
| Ishida, H | 1 |
| Yajima, K | 1 |
| Uehira, T | 1 |
| Mori, K | 1 |
| Mita, E | 1 |
| Gichuhi, S | 1 |
| Macharia, E | 1 |
| Kabiru, J | 1 |
| Zindamoyen, AM | 1 |
| Rono, H | 1 |
| Ollando, E | 1 |
| Wachira, J | 1 |
| Munene, R | 1 |
| Maina, J | 1 |
| Onyuma, T | 1 |
| Sagoo, MS | 1 |
| Weiss, HA | 1 |
| Burton, MJ | 1 |
| Santos, C | 1 |
| Morgan, BW | 1 |
| Geller, RJ | 1 |
| Sparano, JA | 1 |
| Lee, JY | 1 |
| Palefsky, J | 1 |
| Henry, DH | 1 |
| Wachsman, W | 1 |
| Rajdev, L | 1 |
| Aboulafia, D | 1 |
| Ratner, L | 1 |
| Fitzgerald, TJ | 1 |
| Kachnic, L | 1 |
| Mitsuyasu, R | 1 |
| Das, M | 1 |
| Berretta, M | 5 |
| Di Benedetto, F | 3 |
| Bearz, A | 5 |
| Simonelli, C | 3 |
| Martellotta, F | 2 |
| Del Ben, C | 1 |
| Berretta, S | 4 |
| Spina, M | 4 |
| Tirelli, U | 5 |
| Lleshi, A | 3 |
| Zanet, E | 2 |
| Fisichella, R | 2 |
| Nasti, G | 2 |
| Hogg, ME | 1 |
| Popowich, DA | 1 |
| Wang, EC | 1 |
| Kiel, KD | 1 |
| Stryker, SJ | 1 |
| Halverson, AL | 1 |
| Fraunholz, I | 1 |
| Weiss, C | 1 |
| Eberlein, K | 1 |
| Rödel, C | 1 |
| Cappellani, A | 1 |
| Talamini, R | 1 |
| Cacopardo, B | 1 |
| Nunnari, G | 1 |
| Montesarchio, V | 1 |
| Izzi, I | 1 |
| Lanzafame, M | 1 |
| Basile, F | 1 |
| Schiantarelli C, C | 1 |
| Garlassi, E | 1 |
| Ridolfo, A | 1 |
| Guella, L | 1 |
| Abbas, A | 1 |
| Yang, G | 1 |
| Fakih, M | 1 |
| Wieland, U | 1 |
| Brockmeyer, NH | 1 |
| van Noesel, C | 1 |
| Potthoff, A | 1 |
| Kreuter, A | 1 |
| Hauerstock, D | 1 |
| Ennis, RD | 1 |
| Grossbard, M | 1 |
| Evans, A | 1 |
| Alfa-Wali, M | 1 |
| Allen-Mersh, T | 1 |
| Antoniou, A | 1 |
| Tait, D | 1 |
| Newsom-Davis, T | 1 |
| Gazzard, B | 2 |
| Nelson, M | 2 |
| Bower, M | 2 |
| Sánchez-Jiménez, C | 1 |
| Olivares, I | 1 |
| de Ávila Lucas, AI | 1 |
| Toledano, V | 1 |
| Gutiérrez-Rivas, M | 1 |
| Lorenzo-Redondo, R | 1 |
| Grande-Pérez, A | 1 |
| Domingo, E | 1 |
| López-Galíndez, C | 1 |
| Fox, PA | 1 |
| Dummer, R | 1 |
| Beyeler, M | 1 |
| Morcinek, J | 1 |
| Burg, G | 1 |
| Blazy, A | 1 |
| Hennequin, C | 1 |
| Gornet, JM | 1 |
| Furco, A | 1 |
| Gérard, L | 1 |
| Lémann, M | 1 |
| Maylin, C | 1 |
| Edelman, S | 1 |
| Johnstone, PA | 1 |
| Oehler-Jänne, C | 1 |
| Seifert, B | 1 |
| Lütolf, UM | 1 |
| Ciernik, IF | 1 |
| Danso, D | 1 |
| Lyons, F | 1 |
| Bradbeer, C | 1 |
| Konstantinopoulos, PA | 1 |
| Schlecht, HP | 1 |
| Bryan, B | 1 |
| Pantanowitz, L | 1 |
| Dezube, BJ | 1 |
| De Ruvo, N | 1 |
| Drigo, A | 1 |
| Bottomley, DM | 1 |
| Aqel, N | 1 |
| Selvaratnam, G | 1 |
| Phillips, RH | 1 |
| Peddada, AV | 1 |
| Smith, DE | 1 |
| Rao, AR | 1 |
| Frost, DB | 1 |
| Kagan, AR | 1 |
| Constantinou, EC | 1 |
| Daly, W | 1 |
| Fung, CY | 1 |
| Willett, CG | 1 |
| Kaufman, DS | 1 |
| DeLaney, TF | 1 |
| Höcht, S | 1 |
| Wiegel, T | 1 |
| Kroesen, AJ | 1 |
| Berdel, WE | 1 |
| Runkel, N | 1 |
| Hinkelbein, W | 1 |
| Maiman, M | 1 |
| Watts, DH | 1 |
| Andersen, J | 1 |
| Clax, P | 1 |
| Merino, M | 1 |
| Kendall, MA | 1 |
| Cleator, S | 1 |
| Fife, K | 1 |
| Phillips, R | 1 |
| Pehoushek, J | 1 |
| Smith, KJ | 1 |
| Hanna, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions[NCT03113942] | Phase 2 | 26 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Efficacy and Safety of Topical Trichloroacetic Acid vs. Electrocautery for the Treatment of Anal Intraepithelial Neoplasia in HIV-positive Patients (TECAIN) - a Randomized Controlled Trial[NCT02615860] | 560 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons[NCT02437851] | Phase 2 | 16 participants (Actual) | Interventional | 2015-04-30 | Active, not recruiting | ||
| Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma[NCT00324415] | Phase 2 | 45 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in absolute CD4 counts from start of treatment to 1 year after completion of study treatment (NCT00324415)
Timeframe: 1 year following treatment discontinuation
| Intervention | cells/mm3 (Median) |
|---|---|
| Combined Modality Therapy | 102 |
Percentage of participants who are alive and have not had a colostomy (NCT00324415)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Combined Modality Therapy | 92.4 |
Incidence of opportunistic illnesses, including the development of AIDS during and for 1 year after completion of study treatment (NCT00324415)
Timeframe: 1 year following treatment discontinuation
| Intervention | participants (Number) |
|---|---|
| Combined Modality Therapy | 4 |
Patients will be classified into two groups for purposes of primary endpoint analysis: failure or no failure at 3 years (in the primary analysis, patients lost to follow-up prior to 3 years will be considered failures). For the secondary endpoint of objective response, patients will be classified as responders (NCT00324415)
Timeframe: 3 years following treatment discontinuation
| Intervention | participants (Number) |
|---|---|
| Combined Modality Therapy | 23 |
Number of participants with complete and partial responses based on the RECIST criteria (NCT00324415)
Timeframe: 3 years following treatment discontinuation
| Intervention | participants (Number) |
|---|---|
| Combined Modality Therapy | 30 |
Percentage of participants who are alive at one year (NCT00324415)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Combined Modality Therapy | 92.8 |
Progression-free survival at 1 year is the percentage of patients who are alive and have not experienced progressive disease, defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started, or the appearance of one or more new lesions. (NCT00324415)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Combined Modality Therapy | 87.3 |
EORTC QLQ-C30 Global Score at 1 year. The EORTC QLQ-C30 is a validated questionnaire that evaluates quality of life. The global score is an overall score for quality of life that ranges from 0 to 100. Higher scores indicate between quality of life (NCT00324415)
Timeframe: 1 year
| Intervention | units on a scale (Mean) |
|---|---|
| Combined Modality Therapy | 78.9 |
Percentage of participants who are alive and have not experienced progressive disease and have not relapsed (NCT00324415)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Combined Modality Therapy | 83.1 |
Delayed toxicities are defined as toxicities that occur over 90 days following treatment completion (NCT00324415)
Timeframe: 90 days following treatment discontinuation
| Intervention | events (Number) |
|---|---|
| Combined Modality Therapy | 5 |
5 reviews available for fluorouracil and HIV Coinfection
| Article | Year |
|---|---|
FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highl | 2008 |
Management of anal cancer in 2010. Part 2: current treatment standards and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2010 |
Treatment options for anal intraepithelial neoplasia and evidence for their effectiveness.
Topics: Adult; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Anus Neoplasms; Cido | 2012 |
[Cutaneous neoplasms].
Topics: Adjuvants, Immunologic; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bio | 2003 |
Cervical screening and management of cervical intraepithelial neoplasia in HIV-positive women.
Topics: Antiretroviral Therapy, Highly Active; Female; Fluorouracil; Follow-Up Studies; Forecasting; HIV Inf | 2006 |
5 trials available for fluorouracil and HIV Coinfection
34 other studies available for fluorouracil and HIV Coinfection
| Article | Year |
|---|---|
Validation of actinic keratosis diagnosis and treatment codes among veterans living with HIV.
Topics: Fluorouracil; HIV Infections; Humans; International Classification of Diseases; Keratosis, Actinic; | 2022 |
Correlation of antifungal susceptibility and sequence types within Cryptococcus neoformans VNI from HIV patients, and ERG11 gene polymorphism.
Topics: Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Democratic Republic of t | 2023 |
Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2020 |
Chemotherapy, "Lighting the Fire" or "Releasing the Brakes" in Metastatic Anal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Catheter A | 2017 |
Intralesional 5-fluorouracil to treat extensive molluscum contagiosum in an immunocompromised patient: A novel therapeutic modality.
Topics: Antimetabolites; Facial Dermatoses; Female; Fluorouracil; HIV Infections; Humans; Immunocompromised | 2018 |
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
Topics: Aged; Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Chemor | 2020 |
Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2013 |
Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; | 2014 |
Review of anal cancer patients at the Ottawa hospital.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 2015 |
[Squamous cell carcinoma of the anal canal treated with chemoradiotherapy in a patient with HIV].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Che | 2016 |
The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate.
Topics: Acetates; Antimetabolites, Antineoplastic; Anus Neoplasms; Depression; Drug Overdose; Emergency Medi | 2017 |
Cetuximab chemoradiotherapy in HIV-associated anal cancer.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms | 2017 |
Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Acti | 2008 |
HIV and anal cancer outcomes: a single institution's experience.
Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvan | 2009 |
Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy | 2010 |
Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antir | 2010 |
Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.
Topics: Administration, Topical; Adult; Aged; AIDS-Related Opportunistic Infections; Antimetabolites, Antine | 2010 |
Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.
Topics: Administration, Topical; Adult; Aged; AIDS-Related Opportunistic Infections; Antimetabolites, Antine | 2010 |
Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.
Topics: Administration, Topical; Adult; Aged; AIDS-Related Opportunistic Infections; Antimetabolites, Antine | 2010 |
Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.
Topics: Administration, Topical; Adult; Aged; AIDS-Related Opportunistic Infections; Antimetabolites, Antine | 2010 |
Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2010 |
Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; CD4 Lymph | 2012 |
Mutagen-mediated enhancement of HIV-1 replication in persistently infected cells.
Topics: Cell Line; Deoxycytidine; Fluorouracil; Gemcitabine; HIV Infections; HIV-1; Humans; Mutagens; Mutati | 2012 |
Anti-cancer agents. Cream reduces reappearance of cervical lesions.
Topics: Administration, Topical; Adult; Antimetabolites, Antineoplastic; CD4 Lymphocyte Count; Female; Fluor | 2000 |
Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Anus Ne | 2005 |
Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Capeci | 2006 |
Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cis | 2006 |
HIV-associated anal squamous cell cancer: an otherwise preventable disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Anus Neoplasm | 2006 |
Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Epidermoid anal cancer in HIV infected patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Combined M | 1996 |
Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 1997 |
Time-dose considerations in the treatment of anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Anus Neoplasms; Combine | 1997 |
Low acute toxicity of radiotherapy and radiochemotherapy in patients with cancer of the anal canal and HIV-infection.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Dr | 1997 |
5-FU for cervical intraepithelia neoplasia.
Topics: Administration, Intravaginal; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluor | 2000 |
Treatment of HIV-associated invasive anal cancer with combined chemoradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Fl | 2000 |
Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man.
Topics: Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma in Situ; | 2001 |
5-FU for maintenance therapy of cervical lesions.
Topics: Administration, Intravaginal; Antimetabolites, Antineoplastic; Female; Fluorouracil; HIV Infections; | 1999 |